Category Archives: News

819 Capital Partners invests in UK-based Vidiia Ltd.

819 Capital Partners

819 Capital Partners has recently invested in Vidiia Ltd. from 819 Evergreen Fund, alongside a bio-scientist entrepreneur, the University of Surrey and Brunel University London.

 

 

 

Accelerating the growth strategy

Vidiia commercialises a fast and accurate molecular diagnostic testing platform with built-in Artificial Intelligence (AI). The new funding will be used to accelerate the company’s growth strategy.

David Rimer, CEO and Founder of Vidiia: “With the funds we can implement our growth strategy, which aims to commercialise existing assays ready for market, develop new assays with universities and enhance our AI powered testing platform. Vidiia’s Assay Accelerator service, pulls tests off university benches and gets them to market, which we have now proven several times.”

Strong testing platform

Vidiia has a strong testing platform, which is explained by Dr Nick Hutchings, one of the investors in this round: “Assays are reproducible tools that allow us to understand medicine and biology at a molecular level. I am excited to join Vidiia and help scientists to develop and commercialise new assays on the world class Vidiia platform.”

Sven Kempers, director at 819 Capital Partners, expresses trust in Vidiia’s platform and team: “Vidiia’s technology provides many testing options for rapid diagnoses. We are confident that the team will successfully execute the growth strategy.”

Academic validation

Vidiia has strong support from academic institutions, such as Brunel University London and University of Surrey.

Dr Averil Horton – Head of Business Development and Innovation, Brunel University London – explains: “The Vidiia Assay Development Programme has enabled Brunel to place innovative bio-science IP within a structured framework to commercialisation. Their methodology and AI powered testing platform mean they have the end-to-end knowledge and tools for success.”

Professor Lisa Collins – Pro-Vice-Chancellor, Research and Innovation at the University of Surrey – said: “It is fantastic to see the groundbreaking research of our scientists being brought to market with the help of Vidiia. It is important that the scientific community and industry partners continue to work together to develop innovative testing products to identify infectious diseases.”

Professor Roberto La Ragione – Professor of Veterinary Microbiology and Pathology, School of Veterinary Medicine, and Head of the School of Biosciences at the University of Surrey – said: “Infectious diseases remain a global threat to human and animal health, and our economies. Funding is necessary to enable Vidiia and our scientists to continue our work in developing highly accurate and rapid tests to prevent the next pandemic.”

Hands-on experience

David Rimer, concludes that investment brings more than just the funding: “We are delighted to be working with 819 and Dr Nick Hutchings. Both parties bring the crucial hands-on experience and connections that Vidiia were looking for. The continued support from our university partners also provides a significant boost beyond financial investment.”

819 Capital Partners invested in Vidiia Ltd. from 819 Evergreen Fund.

More information about Vidiia Ltd. on: https://vidiia.com/

Categories: News

Tags:

Aryza acquires Axcess Consulting

Pollenstreet

Pollen Street Capital are pleased to announce that Aryza has acquired Axcess Consulting Pty Ltd (“Axcess”), an Australian headquartered provider of loan management software to blue chip financial services companies across Australia, UK, Ireland, New Zealand, Asia and North America.

Founded in Geelong in 1991, the Axcess platform is a scalable SaaS offering designed to help banks, non-bank lenders, and debt purchasers manage loan origination, underwriting, servicing and investment portfolio management using a single consolidated platform.

Aryza’s acquisition of Axcess will expand its reach in the APAC region, a geography with significant potential for further expansion and cross-selling of Aryza’s broader lending and debt management software solutions. Axcess and its customers will benefit from being part of the Aryza group, tapping into the product innovation within Aryza’s existing loan management software division as well as the group’s global reach.

The transaction, which is Aryza’s 11th acquisition since 2018, supports its mission to be the leading global provider of software solutions across the entire credit-debt lifecycle. Aryza has built a strong end-to-end proposition targeting administratively intense, regulated and data driven processes across lending and debt management, delivering significant gains in efficiency and effectiveness for its clients.

Colin Brown, CEO at Aryza, commented:

“This strategic move aligns perfectly with our mission to expand our global footprint and deliver innovative financial solutions to a wider audience. Axcess Consulting’s expertise and local market knowledge complement Aryza’s technological capabilities, creating a powerful synergy that will enhance our service offerings and provide greater value to our clients. We look forward to driving growth and innovation in the financial services industry across Australia.”

Anastasia Kovaleva, Partner at Pollen Street Capital, added:

“We are pleased to welcome Axcess to the Aryza group and to add a high-calibre name to our footprint in the APAC region, which we see as an exciting opportunity for further growth. Axcess brings 30+ years of experience in LMS in the region, enhancing Aryza’s product offering and customer reach. The acquisition is a continuation of Aryza’s strategy to become a global leader in automating processes across the credit cycle.”

Categories: News

Tags:

Tikehau Capital completes the sale of its stake in Preligens to Safran

Tikehau

Tikehau Capital, the global alternative asset manager, today completes the acquisition by Safran of its stake in Preligens, a world leader in artificial intelligence (AI) for aerospace and defence, for an enterprise value of €220 million. Following an exclusive negotiation process that began in June 2024, Tikehau Capital is selling its stake in Preligens to Safran.

Founded in 2016 by two French engineers, Preligens provides field-proven Artificial Intelligence (AI) analysis solutions for high-end imagery, full-motion video and acoustic signals.

Tikehau Capital’s investment in November 2020 has played a key role in accelerating the growth of Preligens, which has increased revenues tenfold (from €3 million to nearly €30 million), expanded operations in the US and Asia, and now employs around 250 people, including 140 R&D engineers. This sale is the first divestment of Brienne III, the first vintage of the Group’s private equity strategy dedicated to cybersecurity. This strategy has raised almost 4001million euros over its two vintages and has now invested 150 million euros in 16 companies including Trustpair, Chapsvision and Egerie in France and VMRay in Germany. This transaction generates a MOIC of 2.4x and a gross IRR of 30.4%2. 1Brienne III raised €175 million, making it Europe’s largest fund dedicated to cybersecurity. The next vintage announced a closing of €200 million in October 2023, exceeding the final size of the predecessor fund.

22.1x net MOIC and 18% net IRR 1 PRESS RELEASE  PARIS, 2 SEPTEMBER 2024 PRESS CONTACTS: Tikehau Capital: Valérie Sueur +33 1 53 59 03 64 UK – Prosek Partners: Philip Walters – +44 (0) 7773 331 589 USA – Prosek Partners: Trevor Gibbons – +1 646 818 9238 press@tikehaucapital.com SHAREHOLDER AND INVESTOR CONTACTS: Louis Igonet – +33 1 40 06 11 11 Théodora Xu – +33 1 40 06 18 56 shareholders@tikehaucapital.com

ABOUT TIKEHAU CAPITAL: Tikehau Capital is a global alternative asset management group with €46.1 billion of assets under management (at 30 June 2024). Tikehau Capital has developed a wide range of expertise across four asset classes (private debt, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Tikehau Capital is a founder-led team with a differentiated business model, a strong balance sheet, proprietary global deal flow and a track record of backing high quality companies and executives. Deeply rooted in the real economy, Tikehau Capital provides bespoke and innovative alternative financing solutions to companies it invests in and seeks to create long-term value for its investors, while generating positive impacts on society. Leveraging its strong equity base (€3.1 billion of shareholders’ equity at 30 June 2024), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 762 employees (at 30 June 2024) across its 17 offices in Europe, Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit: www.tikehaucapital.com.

DISCLAIMER: The strategy mentioned in this press release is reserved for professional investors and is managed by Tikehau Investment Management SAS, a portfolio management company approved by the AMF since 19/01/ 2007 under the number GP-07000006. Non-contractual document intended exclusively for journalists and media professionals. The information is provided for the sole purpose of enabling them to have an overview of the transactions, whatever the use they make of it, which is exclusively a matter of their editorial independence, for which Tikehau Capital declines all responsibility. This document does not constitute an offer to sell securities or investment advisory services. This document contains only general information and is not intended to represent general or specific investment advice. Past performance is not a reliable indicator of future results and targets are not guaranteed. Certain statements and forecasted data are based on current forecasts, prevailing market and economic conditions, estimates, projections and opinions of Tikehau Capital and/or its affiliates. Owing to various risks and uncertainties actual results may differ materially from those reflected or expected in such forward-looking statements or in any of the case studies or forecasts. Tikehau Capital accepts no liability, direct or indirect, arising from the information contained in this document. Tikehau Capital shall not be liable for any decision taken on the basis of any information contained in this document. All references to Tikehau Capital’s advisory activities in the US or with respect to US persons relate to Tikehau Capital North America. 2

Categories: News

Tags:

Biotalys Receives Approval for Large-Scale Demonstration Trials of EVOCA in the Netherlands

GIMV

Ghent, BELGIUM – 2 September 2024, 07:00 CEST – Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced it received approval by the Dutch regulator CTGB (College voor de Toelating van Gewasbeschermingsmiddelen en Biociden) for large-scale demonstration trials in greenhouses of its first biofungicide candidate, EVOCA™*. Importantly, the harvested fruits and vegetables can be sold for human consumption.

Jeannette Vriend, Plant protection specialist at Dutch growers association Glastuinbouw Nederland, said: “We are very pleased that this innovative technology can now be tested at large scale by growers. Given the many challenges to adequately control fungal diseases in tomatoes, cucumbers and strawberries, due to a sharply shrinking crop protection product package, we really need the acceleration of new, green solutions. These trials offer an ideal opportunity to properly implement such solutions in these high-value integrated crops.”

The CTGB granted Biotalys the approval to test EVOCA against powdery mildew in 40 hectares of tomatoes, 20 hectares of cucumbers and 10 hectares of strawberries. Produce from these greenhouse trials is allowed to be sold for human consumption, an exemption to standard practices requiring crop destruction when a crop protection product is used that has not yet received regulatory approval.**

*download the complete PR

Categories: News

Tags:

Yellowtail Conclusion acquires Fortrum

NPM Capital

Yellowtail Conclusion is acquiring Fortrum, which will give it a significant edge in the area of mortgage and risk management. The acquisition will allow Yellowtail Conclusion to expand the range of services it offers its clients and to provide more innovative solutions. Yellowtail Conclusion is part of the Conclusion ecosystem, an NPM participation.

Yellowtail Conclusion acquires Fortrum

 

Fortrum is based in Houten and was established in 2018 by Michel van der Sluis, Jaap van Raak, Simon Collingridge, and Tony Ward. Fortrum offers consultancy services in the area of risk, governance and compliance and is also specialised in carrying out due diligence, for which it developed the FortApp. The acquisition adds a group of expert professionals to the Yellowtail Conclusion team and offers major benefits in terms of scale and synergy.

 

This strategic acquisition will enable clients to benefit from the combined expertise and innovative solutions offered by Fortrum, Yellowtail Conclusion, and Davinci Conclusion. Their collaboration will make it possible for all three organisations to offer an unparalleled package of services and software solutions to clients in the mortgage and credit market, thereby covering the entire value chain.

 

More information is available at the Yellowtail Conclusion website.

Categories: News

Tags:

Acquisition Spaans Babcock

Anders Invest

Anders Invest has acquired screw pump manufacturer Spaans Babcock from Balk. The company has an annual turnover of €20 to €25 million and employs over 100 people.

Spaans Babcock engineers, produces, builds and installs screw pumps, screw generators, grids and aeration for wastewater treatment plants, pumping stations and hydroelectric power plants. The company is over 125 years old and was founded in 1897 by the Spaans family. In 1974, the company became part of the FKI Group Ltd., which also had a Babcock company in its group, and the current company name was created. In 1995, the company was acquired by the Alpha Group International.

The company realises the majority of its turnover with screw pumps, aerators and hydro turbines, in which niche the company is the global market leader. A large production location is located in Balk where the screw pumps are produced using CNC-controlled machines and welding robots. The screw pump distinguishes itself from other pumping techniques because of its capacity, lifespan, insensitivity to contaminated liquids and energy efficiency. In addition, the screw is fish-friendly and maintains the biological balance in purification plants because the pump has no destructive effect on the composition of the liquid. In addition to the branch in Balk, there are branches in England and Canada/United States.

The end customers are generally (waste) water purification companies, water boards (for example polder pumping stations) and companies active in the construction or operation of sewage treatment. With its own sales offices in England (Heywood) and Canada (Ontario), Spaans Babcock supplies its products worldwide.

The shares in Spaans Babcock were acquired from Alpha Group International.  The Alpha Group is an investment vehicle of Mr. Nolst Trenité and Mr. Eijt. Mr. Eijt is general manager at Spaans Babcock and will remain as general manager and shareholder.

Categories: News

Tags:

Investment in HTC Group

Anders Invest

Anders Invest has acquired a minority stake in HTC Group from Waddinxveen. HTC is the Dutch market leader in speed gates and employs over 80 people.
HTC is known for its high-quality products and innovative custom solutions. For example, the company has introduced mobile speed gates for temporary applications and produces speed gates with safety standards up to and including RC5. HTC has developed a product-as-a-service model and is investing in sustainability by developing the circular speed gate.
The company’s head office is located in Waddinxveen, where the production and assembly of the speed gates also takes place. From this location, the company carries out service and maintenance work with a nationwide network. HTC has its own engineering branch for the development of its products. Sales take place from the Netherlands and through a dealer network in Europe. Its customers are parking managers, government institutions, installers and homeowners’ associations.
The shares in HTC were acquired from Peter Thun. In addition to Anders Invest, operational director Robert-Jan Karsman has joined as a shareholder. Peter will remain as general manager and majority shareholder.

Categories: News

Tags:

Platinum Equity Acquires Controlling Stake in Inventia Healthcare

Platinum

Acquisition of Mumbai-based generic pharmaceutical business led by Platinum’s Asia investment team

LOS ANGELES and MUMBAI (August 28, 2024) – Platinum Equity announced today the acquisition of a controlling stake in Inventia Healthcare Limited’s core Oral Solid Dosage (“OSD”) business (“Inventia”) from India Life Sciences Fund III (Advised by InvAscent), NYLIM Jacob Ballas India Fund III, LLC, Mauritius and affiliates of the company’s founding Shah family (collectively, the “Sellers”).

The Shah family is retaining a minority stake in Inventia. Invengene and Nutriventia, the injectables and nutraceuticals businesses, respectively, are not part of the transaction and are being retained separately by the Shah family.

Financial terms of the acquisition were not disclosed.

“India’s generics sector is well established with attractive long-term growth characteristics, and serves a key role in supplying the pharmaceuticals market globally. Inventia has built a differentiated B2B business that supplies both emerging and mature markets with high-quality products through its longstanding customer relationships and proven drug development and manufacturing capabilities. We intend to help Inventia build upon that strong foundation, expand its reach and further enhance the company’s technology platform and delivery capabilities.”

Jacob Kotzubei, Co-President, Platinum Equity

“India’s generics sector is well established with attractive long-term growth characteristics, and serves a key role in supplying the pharmaceuticals market globally,” said Platinum Equity Co-President Jacob Kotzubei. “Inventia has built a differentiated B2B business that supplies both emerging and mature markets with high-quality products through its longstanding customer relationships and proven drug development and manufacturing capabilities. We intend to help Inventia build upon that strong foundation, expand its reach and further enhance the company’s technology platform and delivery capabilities.”

Headquartered in Mumbai, Inventia was jointly founded in 1985 by the company’s late chairman and managing director Janak Shah and executive director Maya Shah. Today, Inventia serves as a partner to over 100 customers supplying both semi-finished and finished OSD formulations for both regular and value-added generics. Inventia’s partners include global and leading local pharmaceuticals companies that sell in more than 40 countries across North America, South America, Europe, Southeast Asia, Middle East and Africa.

Inventia operates a manufacturing facility in Ambernath and a research and development facility in Thane in Maharashtra, India. The company’s manufacturing platform is accredited by the U.S. FDA, U.K. MHRA and other Stringent Regulatory Authorities (“SRA”).

“This investment marks a significant milestone in the journey of Inventia. As founders and long-standing stewards of the company, we are thrilled to see Platinum Equity’s investment in our core OSD business,” said Maya Shah and the late Janak Shah in a joint statement prior to Janak Shah’s recent passing. “This partnership will harness Inventia’s strengths and Platinum’s operational expertise to propel us to new heights. We remain deeply committed to our mission and are confident that this collaboration will drive further innovation and growth. Our vision for Inventia has always been to provide high-quality, accessible pharmaceutical products, and with Platinum Equity, we believe this vision will only grow stronger.”

The acquisition is being led by Platinum Equity’s Asia investment team based in Singapore.

“We believe Inventia is a strong platform for growth in a fragmented market, and our goal is to create a larger, more diversified B2B business focused on the attractive but underserved emerging markets,” said Platinum Equity Managing Director Amit Sobti. “We are excited to build upon the strong foundation set by the Shah family by bringing in our operational and financial resources to further institutionalize the company and set it up for success on a significantly greater scale. Inventia’s current product pipeline can drive strong organic growth over the foreseeable future, which we will look to enhance through acquisitions, with an emphasis on broadening the company’s product portfolio and capabilities.”

Kotzubei said in addition to seeking add-ons for Inventia, Platinum Equity will continue to source platform deals in India that fit the firm’s investment strategy.

“The buyout market in India continues to evolve and there are more opportunities available today that fit our approach,” he explained. “There are more mature companies with more need for operational support, including founder or family-owned businesses seeking a partner who can not only provide capital, but also operational expertise. We have a lot of experience in those situations.”

Barclays served as exclusive financial advisor to Platinum Equity on the transaction. Latham Watkins served as international legal counsel alongside Trilegal as India legal counsel for Platinum Equity. Kirkland & Ellis provided financing counsel to Platinum Equity on the transaction. Rothschild & Co and Stifel Nicolaus India (erstwhile Torreya Partners) served as financial advisors to the Sellers. Quillon Partners served as legal counsel to the Sellers on the transaction.

About Platinum Equity

Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with more than $48 billion of assets under management and a portfolio of approximately 50 operating companies that serve customers around the world. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 28 years Platinum Equity has completed more than 450 acquisitions.

Categories: News

Tags:

Sealing System sold

Polaris

We hereby announce that Sealing System has been sold following the restructuring and most jobs have been retained.

Please see the initial press release concerning the process published on the 30th of August:

English

For more information, please contact:

Allan Bach Pedersen, Partner
Phone: +45 40 30 24 15
Mail: abp@polarisequity.dk

Categories: News

ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan

GIMV

ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France’s 2030 ambitious vision to deliver 20 innovative biomedicines by the end of the decade.

Marseille, France, August 29, 2024, 11 am CET – ImCheck Therapeutics announced today that it has received EUR 20.18 million in non-dilutive funding as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government.

The funding will support the development of the company’s most advanced drug candidate, ICT01, a pathogen-agnostic γ9δ2 T cell-activating monoclonal antibody, currently in a Phase I/IIa clinical trial program in various solid cancer and hematologic malignancy indications.  The funding also supports ImCheck’s ICT41 infectious disease candidate, which is moving toward clinical development.

“We are honored to be supported by the France 2030 innovation plan. It is a tribute to theprogress we have achieved in the clinic and the overall potential of our novel immunotherapeutic programs. Our approach is both unique and polyvalent, enabling us to address solid tumors, hematologic malignancies and infectious diseases. This recognition from the French government and Bpifrance represents their confidence in our first-in-class therapies, which have the potential to significantly improve patients’ lives,” commented Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics. “We look forward to providing updates from the ICT01 clinical development program as well as other corporate advances later this year.”

Categories: News

Tags: